NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate ALN-6222 in Participants With Obesity

RecruitingPhase 1

Sponsor: Alnylam Pharmaceuticals

Conditions: Obesity

Interventions: ALN-6222, Placebo

Countries: Canada

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria -

* Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2
* Has a hemoglobin A1c \<6.5%

Exclusion Criteria -

* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN)
* Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
* Has an estimated glomerular filtration (eGFR) of \<60 mL/min/1.73m\^2 at screening

Note: other protocol defined inclusion / exclusion criteria apply

Locations (1)

Mount Royal, Canada